Home > Insider Trading > Filing (0001209191-12-034147)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1131324	Genomic Health Inc	GHDX	Services-Medical Laboratories (8071)	770552594

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1333482	J Kimberly Popovits	301 Penobscot Drive Redwood City CA 94403	President And Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2012-05-31	919	$23.11	19,523	No	4	P	Direct
Common Stock	Disposition	2012-06-01	750	$0.00	244,906	No	5	G	Indirect	Held by the Popovits 2010 Trust
Common Stock	Disposition	2012-06-01	750	$0.00	244,156	No	5	G	Indirect	Held by the Popovits 2010 Trust
Common Stock	Disposition	2012-06-01	750	$0.00	243,406	No	5	G	Indirect	Held by the Popovits 2010 Trust
Common Stock	Disposition	2012-06-13	5,000	$33.36	238,406	No	4	S	Indirect	Held by the Popovits 2010 Trust

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Direct
No	5	G	Indirect	Held by the Popovits 2010 Trust
No	5	G	Indirect	Held by the Popovits 2010 Trust
No	5	G	Indirect	Held by the Popovits 2010 Trust
No	4	S	Indirect	Held by the Popovits 2010 Trust

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	12,298	Indirect	Held by UBS for Benefit of Kimberly Popovits
Common Stock	14,770	Indirect	Held in trust for the benefit of Ms. Popovits' son, of which Ms. Popovits is trustee.

Footnotes

Includes 10,000 restricted stock units awarded February 5, 2012 which vest as to 1/3 of the shares on February 15, 2013, 1/3 of the shares on February 15, 2014 and 1/3 of the shares on February 15, 2015.
Includes 10,000 restricted stock units awarded January 27, 2011, of which 1/3 of the shares vest on each of February 15, 2013 and 2014, and the 1/3 of the shares that vested on February 15, 2012, net of withholding.
Includes 919 shares purchased through the Company's Employee Stock Purchase Plan.
These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on November 11, 2011.
Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated.
Represents weighted average sale price. Actual sale prices ranged from $33.16 to $33.60.